Clinical study of safety and efficacy of DMA110 topical gel in the treatment of genital wart.

Phase 1

Recruiting

• Conditions: Anogenital (venereal) warts; A63.0; Genital wart.

• Registration Number: IRCT20181026041466N6
• Lead Sponsor: Rayka raya teb co

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 26 May 2021

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

All patients with genital warts

Exclusion Criteria

Patients who need to take immune suppressive drugs such as corticosteroids , chemotheraputic drugs or undergoing radiation therapy.
Patients suffering from immune deficiency-associated diseases such as diabetes, cancer, HIV.
pregnancy
lactation
A wound or active skin disease other than wart at the treatment site

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Side effects from treatment. Timepoint: In 7, 14, 21, 28, 35, 42, 49, 56, 84, 112, 140, 168, 196 and 238 days. Method of measurement: Inspection and clinical examination, Patients' complaints.;Measurement of genital wart size. Timepoint: In 0, 7, 14, 21, 28, 35, 42, 49, 56, 84, 112, 140, 168, 196 and 238 days. Method of measurement: caliper.;Number of warts. Timepoint: In 0, 7, 14, 21, 28, 35, 42, 49, 56, 84, 112, 140, 168, 196 and 238 days. Method of measurement: Clinical counting.